Shield Therapeutics PLC (LON:STX)‘s stock had its “buy” rating reissued by stock analysts at Liberum Capital in a note issued to investors on Tuesday. They currently have a GBX 310 ($4.05) target price on the stock. Liberum Capital’s price objective points to a potential upside of 94.36% from the stock’s current price.

Separately, Canaccord Genuity reiterated a “buy” rating and issued a GBX 235 ($3.07) price objective on shares of Shield Therapeutics PLC in a report on Thursday, August 11th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shield Therapeutics PLC (LON:STX) traded up 2.24% on Tuesday, reaching GBX 159.50. The company’s stock had a trading volume of 53,770 shares. The firm’s market capitalization is GBX 172.48 billion. The company has a 50 day moving average of GBX 156.43 and a 200 day moving average of GBX 166.01. Shield Therapeutics PLC has a 52 week low of GBX 147.00 and a 52 week high of GBX 190.00.

Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with's FREE daily email newsletter.